Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due ...

Investigational BAY 2927088 is an oral, small molecule, tyrosine kinase inhibitor as a potential new targeted therapy for patients with non-small cell lung cancer (NSCLC) harboring HER2 activating ...

The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations.

Many people are familiar with histamine, a biological molecule that serves as a key driver of allergic reactions and other ...

Many people are familiar with histamine, a biological molecule, that serves as a key driver of allergic reactions and other immune responses. However ...